Dose-dependent rapid-onset akathisia with arpiprazole in patients with schizoaffective disorder

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 2, 2006, Pages 241-243

  Basu, Ranita ^a   Brar, Jaspreet S ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Akathisia; Aripiprazole

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; HALOPERIDOL; HYDROXYZINE; LEVOTHYROXINE; LORAZEPAM; MOLINDONE; OLANZAPINE; PAROXETINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; TOPIRAMATE; TRIAZOLAM; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CASE REPORT; CONSCIOUSNESS DISORDER; DEPRESSION; DRUG SUBSTITUTION; EMOTIONAL DISORDER; FEMALE; HEART PALPITATION; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; PSYCHOSIS; RESTLESS LEGS SYNDROME; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SUICIDAL BEHAVIOR; WEIGHT GAIN;

EID: 33745917374     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.2.241     Document Type: Article

References (11)

1. Burris, KD. Molski TF. Xu C, et al. 2002. Aripiprazole, a novel antipsychotic is a high affinity partial agonist at human D2 dopamine receptors. J Pharmacol Exp Ther, 302:381-9.
2. Cohen ST, Rulf D, Pies R. 2005. Extrapyramidal side effects associated with aripiprazole coprescription in two patients. J Clin Psychiatry, 66:135-6.
3. El-Sayeh HG, Morganti C. 2005. Aripiprazole for schizophrenia. The Cochrane Database of Systematic Reviews, Vol I.
4. Gerber PE, Lynd LD. 1998. Selective serotonin reuptake inhibitor induced movement disorders. Ann Pharmacother, 32:692-8.
5. Harrison, Swainston T, Perry CM. 2004. Aripiprazole; A review of its use in schizophrenia and schizoaffective disorder. Drugs, 64:1715-36.
6. Jordan S, Koprivica V, Chen R, et al. 2002. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 441:137-40.
7. Lane RM. 1998. SSRI induced extra pyramidal side effects and akathisia: implications for treatment. J Psychopharmacol, 12:192-214.
8. Lieberman JA. 2004. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs, 18:251-67.
9. Marder SR, McQuade RD, Stock E, et al. 2003. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo controlled trials. Schizophr Res, 61:123-36.
10. Marsden CD, Jenner P. 1980. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Medicine, 10:55-72.
11. Potkin SG, Saha AR, Kujawa MJ, et al. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry, 60:681-90.